"Under the terms of the agreement, at closing all of Anaconda...

"Under the terms of the agreement, at closing all of Anaconda Pharma's outstanding shares will be acquired for 3.5 million shares of Biota common stock and $8.0 million in cash, subject to certain closing and post-closing adjustments. Biota will fund the cash portion of the purchase price with cash on hand. The transaction also includes additional contingent financial consideration of up to $30.0 million, which is based on the successful achievement of certain future clinical and regulatory milestones, plus a royalty

Condyloma represents a significant burden to the health care system with an estimated 385,000 initial visits to physician offices in 2008 and $200 million in direct costs annually in the United States.


Very small market for Condyloma. Very expensive purchase and soon to become a bottomless pit for cash burning.

Why can't they continue with those in house drugs development ?. What the stupid management is thinking now ?.